Economical aspect and possible barriers: Patient organisation perspectiveWritten by Brian O'Mahony
President, European Haemophilia Consortium (EHC)
Brian Oâ€™Mahony is the chief executive of the Irish Haemophilia Society (IHS). He represents IHS on the statutory National Haemophilia Council and he is the vice-chair of the Tender Commission, established by the Irish government for the procurement of factor concentrates. He previously served as IHS chair for 17 years and as president of the World Federation of Hemophilia (WFH) for ten years. He continues to work as a volunteer with the WFH. Among his activities are writing, advocating, and facilitating training. His publications for the WFH include Monographs on Advocacy, Developing Haemophilia Organisations, Economics and Health Technology Assessments and a Guidebook on National Tender Systems.
A medical scientist by profession, he is a fellow of the Institute of Biomedical Sciences (UK) and a Fellow of the Academy of Medical Laboratory Sciences (Ireland). He has post-graduate qualifications in Management and in Occupational Health and Safety. He spearheaded the advocacy initiatives in Ireland, which resulted in the availability of prophylaxis for children and recombinant products for all people with haemophilia, compensation and life insurance for those affected by transfusion-transmitted infections and a formal role for IHS in decisions on national haemophilia health care policy.
He is the convenor of the Platform for Plasma Users (PLUS), which advocates on plasma and blood related issues with European Institutions on behalf of several non-governmental organisations. He served on the Steering Committee of the European Haemophilia Consortium (EHC) from 2007 to 2011. He was elected as president of the EHC in 2011 and re-elected in 2015.
Brian has severe haemophilia B.